Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study of Solid Organ Transplantation Utilizing HIV-Positive Donors in HIV-Positive Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03170414
Recruitment Status : Recruiting
First Posted : May 31, 2017
Last Update Posted : October 18, 2018
Sponsor:
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute

Brief Summary:

The primary objective of this study is to evaluate the safety of solid organ transplantation using HIV-positive deceased donors (liver, kidney) and HIV-positive living donors (liver) in HIV-positive recipients.

HIV-positive individuals who agree to accept and receive a solid organ transplant from and HIV-positive donor will be followed to determine the safety and efficacy of this practice.


Condition or disease
HIV Awaiting Organ Transplant

Detailed Description:

This is a prospective observational study of solid organ transplantation utilizing HIV-positive donors in HIV-positive recipients. Stable HIV-infected adults in need of a solid organ transplant (kidney, liver) who meet standard and study specified HIV criteria for organ transplantation will be offered enrollment in the study. Deceased donors (kidney, liver) and living donors (liver) will be utilized in this protocol. No living kidney donors will be enrolled.

This study will evaluate overall survival and graft survival. In addition the study will assess potential complications of organ transplant using HIV+ donor organs, including but not limited to: HIV disease progression, development of antiretroviral resistance mutations, incidence of opportunistic infections, incidence of transplant complications, impacts of liver regeneration, incidence of viral-related malignancies, and incidence of HIV-superinfection.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 10 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Observational Study of Solid Organ Transplantation Utilizing HIV-Positive Donors in HIV-Positive Recipients
Actual Study Start Date : June 15, 2017
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Group/Cohort
HIV D+/R+
HIV+ recipients who receive an organ transplant from an HIV+ donor



Primary Outcome Measures :
  1. Patient Survival [ Time Frame: One Year ]
    Patient survival at one year.


Secondary Outcome Measures :
  1. Graft Survival [ Time Frame: Months 3, 6, 9, Years 1, 2, 3 ]
  2. Incidence and Severity of Graft Rejection [ Time Frame: Through study completion, up to three years ]
  3. HIV Disease Progression [ Time Frame: Through study completion, up to three years ]
  4. Development of antiretroviral resistance mutations and/or X4 tropic virus in blood and allograft [ Time Frame: Through study completion, up to three years ]
  5. Incidence of bacterial, fungal, viral and other opportunistic infections [ Time Frame: Through study completion, up to three years ]
  6. Incidence of other transplant complications (surgical and vascular) [ Time Frame: Through study completion, up to three years ]
  7. Liver transplant recipients: Impact on liver regeneration [ Time Frame: Through study completion, up to three years ]
  8. Analysis of recurrent HIV associated nephropathy among kidney transplant recipients [ Time Frame: Through study completion, up to three years ]
  9. Incidence of other viral-related malignancies (HPV, EBV, HBV, HCV) [ Time Frame: Through study completion, up to three years ]
  10. Incidence of systemic HIV-superinfection in blood [ Time Frame: Through study completion, up to three years ]
  11. Incidence of tissue specific HIV-superinfection [ Time Frame: Through study completion, up to three years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Stable HIV-infected adults in need of a solid organ transplant (kidney, liver) who meet standard and study specified HIV criteria for organ transplantation will be offered enrollment in the study. Deceased donors (kidney, liver) and living donors (liver) will be utilized in this protocol. No living kidney donors will be enrolled.
Criteria

RECIPIENT ELIGIBILITY CRITERIA HIV-Positive Recipient Inclusion Criteria (liver, kidney)

  1. Participant is able to understand and provide informed consent.
  2. Participant meets standard listing criteria for transplant.
  3. Documented HIV infection (by any licensed ELISA and confirmation by Western Blot, positive HIV ab IFA, or documented history of detectable HIV-1 RNA).
  4. Participant is ≥ 18 years old.
  5. No evidence of active opportunistic complications of HIV infection.
  6. Participant CD4+ T-cell count is >/= 200/µL within 16 weeks prior to transplant for kidney transplant recipients. For liver transplant recipient, CD4+ T-cell counts need to be >/= 100/ul (or >/= 200/µL if history of opportunistic infection) within 16 weeks prior to transplant.
  7. Participant most recent HIV-1 RNA < 50 copies/mL (by any FDA-approved assay performed in CLIA-approved laboratory), in the 26 weeks prior to transplant. Participants unable to tolerate ART due to organ failure or who have only recently started ART may have detectable viral load and still be considered eligible if the study team is confident there will be a safe, tolerable, and effective antiretroviral regimen once organ function is restored after transplantation.
  8. Concurrence by the study team that based on medical history and ART, viral suppression can be achieved in the recipient post-transplant.
  9. No history of primary CNS lymphoma or progressive PML.
  10. On a stable antiretroviral regimen. Participants unable to tolerate ART due to organ failure may still be considered eligible if the study team is confident there will be a safe, tolerable, and effective antiretroviral regimen once organ function is restored after transplantation.

HIV-Positive Recipient Exclusion Criteria (liver, kidney)

1. Participant has concomitant conditions that, in the judgment of the investigators, would preclude transplantation or immunosuppression.

DONOR ELIGIBILITY CRITERIA HIV-Positive Deceased Donor (liver, kidney)

  1. Must meet all clinical criteria for HIV-uninfected organ donors.
  2. No evidence of invasive opportunistic complications of HIV infection.
  3. Pre-implant donor organ biopsy showing no disease process that would put the recipient at increased risk of rapid progression to end-stage organ failure, to be stored for the duration of the study.
  4. Donor has documented HIV infection (by any licensed ELISA and confirmation by Western Blot, positive HIV ab IFA, or history of detectable HIV-1 RNA) from a CLIA-approved laboratory.
  5. If known history of HIV infection and prior antiretroviral therapy, the study team must describe the anticipated post-transplant antiretroviral regimen to be prescribed for the recipient and justify its conclusion that the regimen will be safe, tolerable and effective.

HIV-Positive Living Donor (liver)

  1. Donor meets all clinical criteria to be a living liver donor other than being HIV positive.
  2. Donor has documented HIV infection (by any licensed ELISA and confirmation by Western Blot, positive HIV ab IFA, or history of detectable HIV-1 RNA) from a CLIA-approved laboratory.
  3. No evidence of invasive opportunistic complications of HIV infection
  4. Donor CD4+ T-cell count is >/= 500/µL in the 26 weeks prior to donation.
  5. The most recent HIV-1 RNA has been below 50 copies RNA/ml in the 26 weeks prior to donation.
  6. On a stable antiretroviral regimen.
  7. Must be evaluated by the HIV/Transplant Infectious Diseases team to verify resistance history and current ART regimens. The potential for transmission of resistant strain of HIV will be assessed.
  8. Pre-implant donor liver biopsy to be stored for the duration of the study showing no evidence of a disease process that would put the donor at increased risk of progressing to end-stage organ failure after donation, or that would present a risk of poor graft function to the recipient.
  9. Must be evaluated by an independent HIV study living donor advocate separate from the transplant service in addition to the living donor advocate seen by all living donors.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03170414


Contacts
Layout table for location contacts
Contact: Timothy L Pruett, MD 612-626-7282 tlpruett@umn.edu
Contact: Varvara Kirchner, MD 612-625-5609 kirc0079@umn.edu

Locations
Layout table for location information
United States, Minnesota
University of Minnesota Medical Center Recruiting
Minneapolis, Minnesota, United States, 55454
Contact: Timothy Pruett, M.D.         
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Investigators
Layout table for investigator information
Principal Investigator: Timothy Pruett, MD University of Minnesota - Clinical and Translational Science Institute

Layout table for additonal information
Responsible Party: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier: NCT03170414     History of Changes
Other Study ID Numbers: HIVTR-HOPE
First Posted: May 31, 2017    Key Record Dates
Last Update Posted: October 18, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
HIV
Kidney Transplant
Liver Transplant
Transplant
HOPE Act

Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Seropositivity
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases